HOME > ARCHIVE
ARCHIVE
- FPMAJ Considering Reshuffling of Its Member Associations
February 17, 2003
- On the move
February 17, 2003
- Press Seminar
February 17, 2003
- e-CSO to Reduce Costs: Mr Tanimura of So-net M3
February 17, 2003
- Chugai, Abgenix to Collaborate on Fully-human Monoclonal Antibody Technology
February 17, 2003
- 10 New Products Including Targocid Inj. Calblock Tab. Receive Approval
February 17, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
February 17, 2003
- PFSB Cautions over ADRs for Candesartan, Sulpiride
February 17, 2003
- Outline of Vision for Medical Devices Industry Presented
February 17, 2003
- Government Sticks to 30% Copayment Hike
February 17, 2003
- World news in brief
February 17, 2003
- REGULATORY NEWS IN BRIEF
February 17, 2003
- Meet the Leaders (15)
February 17, 2003
- Dr Calfee Points Out Lack of Freedom Hits Drug Industry in Germany, Japan: PhRMA Seminar
February 17, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
February 17, 2003
- Dainippon Wishes to Sharply Recover from Next Fiscal Year
February 17, 2003
- Report Highlights Growing Profitability of Matsumotokiyoshi
February 17, 2003
- Teijin Aims at \105 Bil. Pharma Sales in FY2005
February 17, 2003
- Voluntary Standards Established for Gingko Biloba, B. Natto Extracts
February 17, 2003
- Mr Nagayama Offers Proposals to Stimulate FDI in Japan
February 17, 2003
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
